News | EP Lab | May 25, 2021

Acutus Gains European CE Mark for Suite of Next Generation EP Products

Expanded and product portfolio strengthens offering in electrophysiology access and therapy guidance

Left, the AcQCross Transseptal Crossing Device offers versatility to be utilized with top sheaths currently used in left atrium EP and structural heart procedures. Right, the AcQMap next-generation mapping catheter integrates high-resolution ultrasound-based imaging and non-contact mapping catheter with improved torque response, handling and maneuverability.

Left, the AcQCross Transseptal Crossing Device offers versatility to be utilized with top sheaths currently used in left atrium EP and structural heart procedures. Right, the AcQMap next-generation mapping catheter integrates high-resolution ultrasound-based imaging and non-contact mapping catheter with improved torque response, handling and maneuverability.

May 25, 2021 — Acutus Medical Inc. announced European CE mark approval for a broad suite of electrophysiology (EP) products that includes the AcQCross family of universal transseptal crossing devices, the next generation AcQGuide MAX and VUE large bore delivery sheaths, and the next generation AcQMap EP mapping catheter. These products are designed to streamline procedural workflow in all left heart procedures and further improve ease-of-use of Acutus’ proprietary non-contact mapping technology, which allows electrophysiologists to quickly and accurately map the most complex atrial arrhythmias in minutes.

“Our R&D investments are translating into meaningful clinical innovations, as we build a comprehensive portfolio of therapy management solutions that make procedures safer, simpler and more effective,” said Vince Burgess, president and CEO of Acutus Medical. “We remain steadfast in our commitment to improve the treatment of complex atrial arrhythmias, and the European launch of our next generation access and diagnostic technologies is another step in that direction.”

The approvals expand on the company’s extensive therapy guidance and ablation product lines already approved in Europe. 

The newly CE marked products include:

AcQCross family of universal transseptal crossing devices: This is the first and only transseptal puncture system specifically engineered to pair and mate seamlessly with market leading sheaths in addition to Acutus’ own offerings. Transseptal crossing devices are used in a range of electrophysiology and structural heart procedures, such as atrial fibrillation ablation, left atrial appendage occlusions, and transcatheter mitral valve repair. The new AcQCross family of catheters include versions that are length-, diameter- and tip-matched and designed to lock into the hub of sheaths now used in the vast majority of left heart procedures, including those provided by Acutus and by other vendors. This unique compatibility allows physicians to utilize AcQCross with their sheath of choice during virtually any left heart procedure.

AcQGuide MAX and VUE steerable sheaths: These sheaths provide improved handling and deliverability that are designed to facilitate even faster anatomy reconstruction and mapping acquisition times when used in conjunction with Acutus’ AcQMap 3D imaging and mapping system. The VUE sheath, which is expected to be launched later this year, will also include tip electrodes intended to facilitate catheter localization and improved workflow in procedures where physicians desire to limit the use of fluoroscopy.

Next-generation AcQMap 3D imaging and mapping catheter: The only integrated high-resolution ultrasound-based imaging and non-contact mapping catheter capable of capturing cardiac imaging information in addition to cardiac electrical activation mapping is enhanced with improved torque response, handling, and maneuverability. AcQMap Catheter’s advanced transducer and electrode design, when partnered with the AcQMap System, allows electrophysiologists to create an anatomical map of the atrial chambers of the heart and map simple and complex electrical patters of the heart in sinus and complex arrhythmias. Improved visualization of the arrhythmia in cardiac tissue allows physicians to employ new approaches to cardiac ablation as evidenced in a recently published article online in the Heart Rhythm Society Journal. Independent investigators found that 87.5% of patients experienced freedom from AF at two years after a single ablation procedure informed by Acutus’ AcQMap System.[1]

In Europe, there are approximately 350,000 cardiac ablations annually. This procedure volume is expected to grow to 475,000 by 2025.[2] The increasing prevalence of complex arrhythmias and the associated burden on patients and healthcare providers requires new solutions from access to diagnosis to therapy.

The AcQCross Universal Transseptal Access System and the second-generation AcQMap 3D imaging and mapping catheter are now commercially available in Europe and the United States. The AcQGuide VUE and second generation AcQGuide MAX are approved in Europe but are not cleared for sale in the United States. 

For more information: www.acutusmedical.com/us/

References:

1. Shi R, et al, An Individualized Ablation Strategy to Treat Persistent Atrial Fibrillation: Core-to-Boundary Approach Guided by Charge-Density Mapping, Heart Rhythm (2021), doi: https://doi.org/10.1016/ j.hrthm.2021.02.014. 

2. 2019 Millennium Research Group: Electrophysiology Mapping and Ablation Devices. Market Analysis. Europe (Supplemental) | 2019
 

Related Content

The Stereotaxis Genesis EP robotic navigation system.

The new generation Stereotaxis Genesis EP robotic navigation system.

News | EP Lab | September 01, 2021
September 1, 2021 — Stereotaxis and Shanghai Microport EP Medtech Co., Ltd.
Ventricular Tachycardia Recurrence, Hospitalization and Death Reduced With Catheter Ablation as First Line Therapy. Results from an international clinical trial show a significant reduction in risk of ventricular tachycardia (VT) recurrence, cardiovascular hospitalization, and sudden cardiac death (SCD) death when catheter ablation is used as an early first-line treatment for patients with structural heart disease. Led by study coordinating center, the University of Chicago, The PAUSE-SCD trial. #HRS21
News | EP Lab | August 09, 2021
August 9, 2021 – Results from an international clinical trial show a significant reduction in risk of ventricular tac
Heart Rhythm Society, HRS, 2021 Late-Breaking Clinical Trials in Electrophysiology. #HRS #HRS2021 #HRS21 #Heartrhythm21
Feature | EP Lab | August 09, 2021
July 28, 2021 — Here is the complete list of late-breaking clinical trials (LBCT) and links to articles on all of the
An example from the study of the Biosense Webster NuVision 3D/4D ICE imaging capability showing the left atrial appendage (LAA) visualization on 3D ICE. The system allows the user to place a false lighting source to be placed in different positions to change the lighting and shadows to better visualize the anatomy.

An example from the study of the Biosense Webster NuVision 3D/4D ICE imaging capability showing the left atrial appendage (LAA) visualization on 3D ICE. The system allows the user to place a false lighting source to be placed in different positions to change the lighting and shadows to better visualize the anatomy. 

News | EP Lab | August 05, 2021 | By Dave Fornell, Editor
August 5, 2021 —  A prospective, non-randomized, multicenter, first-in-human clinical study found good diagnostic and
EP lab ablation catheter. #HRS21 #HRS2021
News | EP Lab | August 03, 2021
August 3, 2021 — A subgroup analysis of the EAST – AFNET 4 study population revealed early initiation of rhythm contr
emporary Spinal cord stimulation (SCS) was effective in suppressing post-operative atrial fibrillation (AF) after coronary artery bypass (CAGB) surgery CABG without any adverse events in a randomized pilot study. The TEmporary Spinal CoRd StiMulatIon to PrevenNt Atrial FibrillaTION AFter Cardiac Surgery (TerminationAF) study was presented as a late-breaking study presented at the 2021 Heart Rhythm meeting, the annual conference of the Heart Rhythm Society (HRS).  #HRS21 #HRS2021
News | EP Lab | August 03, 2021
August 4, 2021 — Temporary Spinal cord stimulation (SCS) was effective in suppressing post-operative...
Oral Contraceptives Cause Increased Risk of Cardiac Events in Woman With Long QT Syndrome. #HRS21 #HRS2021 #womenshealth
News | EP Lab | August 03, 2021
August 3, 2021 – Results from a new clinical trial show an increased risk of cardiac events, like sudden cardiac deat
A recent study unveiled a novel sinus node ablation technique that provides a safe and effective treatment option for patients suffering from symptomatic, drug-resistant inappropriate sinus tachycardia (IST). Results of the Susruta-IST Registry were presented as a late-breaking clinical trial at Heart Rhythm 2021, the annual meeting of the Heart Rhythm Society (HRS). #HRS21 #HRS2021

A novel sinus node ablation technique provides a safe and effective treatment option for patients suffering from symptomatic, drug-resistant inappropriate sinus tachycardia (IST). Results of the Susruta-IST Registry were presented as a late-breaking clinical trial at Heart Rhythm 2021.

News | EP Lab | August 03, 2021
August 3, 2021 – A recent study unveiled a novel sinus node...
The Philips EPD Kodex system for the EP lab.
News | EP Lab | August 03, 2021
August 3, 2021 – A new analysis of the Catheter Ablation vs.
The new Octaray high-density mapping catheter from Biosense Webster has 48 electrodes to enable faster and more detailed electromapping of the heart to better guide ablation procedures.

The new Octaray high-density mapping catheter from Biosense Webster has 48 electrodes to enable faster and more detailed electromapping of the heart to better guide ablation procedures. Photo by Dave Fornell

News | EP Lab | August 03, 2021
August 3, 2021 – Biosense Webster, the global leader in cardiac arrhythmia treatment and part of Johnson & Johnso